HPV16 vaccine shows promise in treating precancerous cervical lesions

A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

A deal? An asset sale? A launch? Everyone is watching next moves for Roivant, BridgeBio

What’s next for two of biotech’s once-cool, now-hot companies? Hot on the heels of critical data readouts, Roivant Sciences and BridgeBio Pharma are enjoying two

August 1, 2023

Plant chemical discovered to prevent biofilm formation

If your teeth have ever felt fuzzy after skipping a brushing, you’ve encountered biofilm-a slimy bacterial layer that clings to surfaces. In medical settings, biofilms

January 11, 2025

Alarmed by popularity of Ozempic and Wegovy, insurers wage multi-front battle

Patients are bracing for “D-Day,” the date their insurance companies will stop covering the drugs. Doctors are getting letters from insurance investigators discouraging new prescriptions.

August 3, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.